LENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ Therapeutics (Nasdaq: LENZ), a late clinical-stage biopharmaceutical company developing an aceclidine-based eye drop for presbyopia, has announced its participation in several upcoming investor conferences. These include:
- Morgan Stanley 22nd Annual Global Healthcare Conference (New York, NY) on September 4, 2024
- Wells Fargo Securities 2024 Healthcare Conference (Boston, MA) on September 5, 2024
- H.C. Wainwright 26th Annual Global Investment Conference (New York, NY) on September 10, 2024
- Cantor Global Healthcare Conference (New York, NY) on September 18, 2024
Management will engage in one-on-one meetings at all events and deliver corporate presentations at the H.C. Wainwright and Cantor conferences. A live audio webcast of the Cantor presentation will be available on the LENZ website for 90 days, with a 30-day replay option.
LENZ Therapeutics (Nasdaq: LENZ), una società biofarmaceutica in fase clinica avanzata che sviluppa un collirio a base di aceclidina per la presbiopia, ha annunciato la sua partecipazione a diverse conferenze per investitori in programma. Queste includono:
- 22a Conferenza Globale sulla Salute di Morgan Stanley (New York, NY) il 4 settembre 2024
- Conferenza sulla Salute 2024 di Wells Fargo Securities (Boston, MA) il 5 settembre 2024
- 26a Conferenza Globale sugli Investimenti di H.C. Wainwright (New York, NY) il 10 settembre 2024
- Conferenza Globale sulla Salute di Cantor (New York, NY) il 18 settembre 2024
La direzione parteciperà a incontri individuali in tutti gli eventi e presenterà relazioni aziendali alle conferenze di H.C. Wainwright e Cantor. Una trasmissione audio in diretta della presentazione di Cantor sarà disponibile sul sito web di LENZ per 90 giorni, con un'opzione di replica per 30 giorni.
LENZ Therapeutics (Nasdaq: LENZ), una compañía biofarmacéutica en etapa clínica avanzada que desarrolla un colirio a base de aceclidina para la presbicia, ha anunciado su participación en varias conferencias de inversores próximas. Estas incluyen:
- 22ª Conferencia Anual Global de Salud de Morgan Stanley (Nueva York, NY) el 4 de septiembre de 2024
- Conferencia de Salud 2024 de Wells Fargo Securities (Boston, MA) el 5 de septiembre de 2024
- 26ª Conferencia Anual Global de Inversión de H.C. Wainwright (Nueva York, NY) el 10 de septiembre de 2024
- Conferencia Global de Salud de Cantor (Nueva York, NY) el 18 de septiembre de 2024
La dirección participará en reuniones uno a uno en todos los eventos y realizará presentaciones corporativas en las conferencias de H.C. Wainwright y Cantor. Una transmisión de audio en vivo de la presentación de Cantor estará disponible en el sitio web de LENZ durante 90 días, con una opción de repetición de 30 días.
LENZ Therapeutics(Nasdaq: LENZ)는 임상 단계가 고급인 생명공학 회사로 노안 치료를 위한 아세클리딘 기반의 안약을 개발하고 있으며, 여러 투자자 회의에 참가할 것이라고 발표했습니다. 이번 회의에는 다음이 포함됩니다:
- 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스(뉴욕, NY) 2024년 9월 4일
- 웰스 파고 증권 2024 헬스케어 컨퍼런스(보스턴, MA) 2024년 9월 5일
- H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스(뉴욕, NY) 2024년 9월 10일
- 칸토 글로벌 헬스케어 컨퍼런스(뉴욕, NY) 2024년 9월 18일
경영진은 모든 행사에서 일대일 회의에 참여하고 H.C. 웨인라이트와 칸토 컨퍼런스에서 회사 프레젠테이션을 진행할 예정입니다. 칸토 발표의 실시간 오디오 웹캐스트는 LENZ 웹사이트에서 90일 동안 이용 가능하며, 30일 동안 재생할 수 있는 옵션이 제공됩니다.
LENZ Therapeutics (Nasdaq: LENZ), une entreprise biopharmaceutique en phase clinique avancée développant des gouttes oculaires à base d'aceclidine pour la presbytie, a annoncé sa participation à plusieurs conférences pour investisseurs à venir. Celles-ci incluent :
- 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley (New York, NY) le 4 septembre 2024
- Conférence 2024 sur la Santé de Wells Fargo Securities (Boston, MA) le 5 septembre 2024
- 26e Conférence Annuelle Mondiale d'Investissement de H.C. Wainwright (New York, NY) le 10 septembre 2024
- Conférence Mondiale sur la Santé de Cantor (New York, NY) le 18 septembre 2024
La direction participera à des réunions individuelles lors de tous les événements et présentera des présentations corporatives lors des conférences H.C. Wainwright et Cantor. Un webinaire audio en direct de la présentation de Cantor sera disponible sur le site web de LENZ pendant 90 jours, avec une option de rediffusion de 30 jours.
LENZ Therapeutics (Nasdaq: LENZ), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das Augentropfen auf Basis von Aceclidin gegenPresbyopie entwickelt, hat seine Teilnahme an mehreren bevorstehenden Investorenkonferenzen angekündigt. Diese umfassen:
- 22. Morgan Stanley Jahrestagung zur globalen Gesundheitsversorgung (New York, NY) am 4. September 2024
- Wells Fargo Securities Gesundheitskonferenz 2024 (Boston, MA) am 5. September 2024
- 26. H.C. Wainwright Jahrestagung zum globalen Investment (New York, NY) am 10. September 2024
- Cantor Global Healthcare Conference (New York, NY) am 18. September 2024
Das Management wird an allen Veranstaltungen Einzelgespräche führen und Unternehmenspräsentationen bei den H.C. Wainwright- und Cantor-Konferenzen halten. Ein Live-Audio-Webcast der Cantor-Präsentation wird auf der LENZ-Website für 90 Tage verfügbar sein, mit einer 30-tägigen Wiederholungsoption.
- None.
- None.
SAN DIEGO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences:
Morgan Stanley 22nd Annual Global Healthcare Conference (New York, NY)
Management will participate in one-on-one meetings on Wednesday, September 4, 2024.
Wells Fargo Securities 2024 Healthcare Conference (Boston, MA)
Management will participate in one-on-one meetings on Thursday, September 5, 2024.
H.C. Wainwright 26th Annual Global Investment Conference (New York, NY)
Management is scheduled to provide a corporate presentation on Tuesday, September 10, 2024 at 12:30 PM ET and participate in one-on-one meetings.
Cantor Global Healthcare Conference (New York, NY)
Management is scheduled to provide a corporate presentation on Wednesday, September 18, 2024 at 10:55 AM ET and participate in one-on-one meetings.
A live audio webcast of the Cantor Global Healthcare Conference corporate presentation can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section for 90 days following the presentation. A replay of the webcast will be available on the Company’s website for 30 days following the event.
About LENZ Therapeutics
LENZ Therapeutics is a late clinical-stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve vision in patients with presbyopia. LENZ’s product candidate, LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for the treatment of presbyopia. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day.” LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
FAQ
What investor conferences will LENZ Therapeutics attend in September 2024?
Will LENZ Therapeutics give presentations at the investor conferences?
Can investors access LENZ Therapeutics' presentation at the Cantor Global Healthcare Conference?
What is the main focus of LENZ Therapeutics' drug development?
